These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
114 related items for PubMed ID: 3092618
21. Electrophysiology, hemodynamic and arrhythmia efficacy model studies on encainide. Gomoll AW, Byrne JE, Antonaccio MJ. Am J Cardiol; 1986 Aug 29; 58(5):10C-17C. PubMed ID: 3092614 [Abstract] [Full Text] [Related]
22. The effects of encainide and its major metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, on experimental cardiac arrhythmias in dogs. Kerr MJ, Allen JD, Harron DW, Shanks RG. J Cardiovasc Pharmacol; 1985 Aug 29; 7(3):449-57. PubMed ID: 2410673 [Abstract] [Full Text] [Related]
25. Encainide: a new antiarrhythmic agent. Wehmeyer AE, Thomas RL. Drug Intell Clin Pharm; 1986 Jan 29; 20(1):9-13. PubMed ID: 3080301 [Abstract] [Full Text] [Related]
29. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism. Turgeon J, Evans WE, Relling MV, Wilkinson GR, Roden DM. Br J Clin Pharmacol; 1991 Sep 29; 32(3):283-8. PubMed ID: 1685663 [Abstract] [Full Text] [Related]
30. Depression of maximum rate of depolarization of guinea-pig ventricular action potentials by metabolites of encainide. Hemsworth PD, Campbell TJ. Br J Pharmacol; 1989 Jun 29; 97(2):619-25. PubMed ID: 2503225 [Abstract] [Full Text] [Related]
31. Effects of encainide and its metabolites on energy requirements for defibrillation. Fain ES, Dorian P, Davy JM, Kates RE, Winkle RA. Circulation; 1986 Jun 29; 73(6):1334-41. PubMed ID: 3084128 [Abstract] [Full Text] [Related]
32. Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide. Bajaj AK, Woosley RL, Roden DM. Circulation; 1989 Oct 29; 80(4):994-1002. PubMed ID: 2551538 [Abstract] [Full Text] [Related]
33. A high-performance liquid chromatographic method for the determination of encainide and its major metabolites in urine and serum using solid-phase extraction. Kazierad DJ, Hoon TJ, Bottorff MB. Ther Drug Monit; 1989 Oct 29; 11(3):327-31. PubMed ID: 2499083 [Abstract] [Full Text] [Related]
34. [Anti-arrhythmia effect of long-term encainide in chronic ventricular extrasystole]. Dumoulin P, Jaillon P, Kher A, Poirier JM, Cheymol G, Valty J, Flammang D, Coumel P, Medvedowsky JL, Barnay C. Arch Mal Coeur Vaiss; 1985 Oct 29; 78 Spec No():105-9. PubMed ID: 2420299 [Abstract] [Full Text] [Related]
36. Spectrum of antiarrhythmic response to encainide. Duff HJ, Roden DM, Carey EL, Wang T, Primm RK, Woosley RL. Am J Cardiol; 1985 Nov 15; 56(13):887-91. PubMed ID: 3933319 [Abstract] [Full Text] [Related]
37. Encainide. A review of its pharmacological properties and therapeutic efficacy. Brogden RN, Todd PA. Drugs; 1987 Nov 15; 34(5):519-38. PubMed ID: 3121275 [Abstract] [Full Text] [Related]
38. Analysis of encainide and metabolites in plasma and urine by high-performance liquid chromatography. Bartek MJ, Mayol RF, Boarman MP, Gammans RE, Gallo DG. Ther Drug Monit; 1988 Nov 15; 10(4):446-52. PubMed ID: 3144068 [Abstract] [Full Text] [Related]